問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

Division of Thoracic Medicine

Division of Urology

Digestive System Department

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Urology

Division of Urology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Urology

Division of Hematology & Oncology

更新時間：2023-09-19

劉明哲LIU, MING-CHE
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

Recruiting Trial

23Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉明哲

List

43Cases

2020-09-25 - 2022-11-17

Phase I/II

A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects with Mild to Moderate Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis (AD)

  • Test Drug

    AR100DP1

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2016-02-01 - 2017-01-31

Phase I

A randomized, double-blind, placebo-controlled, single ascending dose first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CFZ533 in healthy subjects and rheumatoid arthritis patients

  • Condition/Disease

    Rheumatoid arthritis

  • Test Drug

    CFZ533

Participate Sites
1Sites

Terminated1Sites

劉明哲
Taipei Medical University Hospital

Division of Urology

2017-07-01 - 2018-09-30

Phase II

A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers

  • Condition/Disease

    Influenza Virus Vaccine

  • Test Drug

    AD07030

Participate Sites
5Sites

Terminated5Sites

劉明哲
Taipei Medical University Hospital

Division of Urology

李文生
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB